

Supplementary Material

Azole resistance mechanisms in pathogenic *M. furfur*

*Cheryl Leong*¹, *Joel Chan Wai Kit*¹, *Shi Mun Lee*¹, *Yuen In Lam*¹, *Joleen P.Z. Goh*¹,
*Giuseppe Ianir*², and *Thomas L. Dawson, Jr*^{1,3#}

¹Skin Research Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore,

²Department of Agricultural, Environmental and Food Sciences, University of Molise, 86100, Campobasso, Italy

³Center for Cell Death, Injury & Regeneration, Departments of Drug Discovery & Biomedical Sciences and Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, SC

#Address correspondence to:

Thomas Dawson

Skin Research Institute of Singapore

11 Mandalay Road, #17-01,

Singapore 308232

Supplementary Figures

Supplementary Figure 1. Conserved motifs in *M. furfur* CYP51

Supplementary Figure 2. Y67F mutation at nucleotide level

Supplementary Figure 3. Validation of *PDR10* gene KO

Supplementary Tables

Supplementary Table 1. MIC values for 26 *M. furfur* isolates

Supplementary Table 2. Top 20 upregulated genes in comparison of untreated CBS 7982, CBS 7019 and CBS 14141- Excel sheet

Supplementary Table 3. MIC values for CBS 7982 over six weeks

Supplementary Table 4. Genes upregulated after clotrimazole treatment – Excel sheet

Supplementary Table 5. Transporter genes upregulated after clotrimazole treatment - Excel sheet

Supplementary Table 6. Primer sequences

Supplementary Figure 1:

Conserved regions of *CYP51A1* *M. globosa* (reference sequence) versus *M. furfur*


Key conserved *CYP51* gene regions identified in *M. globosa*¹

- Putative heme-binding site (⁴⁷¹FGAGRHCIG⁴⁸⁰)
- EXXR motif (³⁶⁵ERLR³⁶⁸)
- Conserved threonine of I-helix involved in proton delivery (³⁰⁷T)

	307T	
CBS 7966 <i>M. globosa</i>	LMAGQHTSSATGSWAMLRLASRPEIIIEELYEEQKRVYSDGTGGFAPLDYDIQKSSVPVLD	360
CBS 1878_scaffold345	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
CBS 7982	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
CBS 1878_scaffold589	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
CBS 4172	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
CBS 7110	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
CBS 14141	LMAGQHTSSATGSWAMLRLASRPKFIQMLYEEQVRVYGE PDGTFKPLNYDTQKSSVPVLD	300
	*****:*: *****: * * **:* *****	
	365EXXR³⁶⁸ motif	
CBS 7966 <i>M. globosa</i>	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAAPISS--KGRDETYVIPKGHYVIAAPGV	418
CBS 1878_scaffold345	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
CBS 7982	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
CBS 1878_scaffold589	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
CBS 4172	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
CBS 7110	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
CBS 14141	AVIFETLR LHPPHHSIMRKVKSDIPVPPTLAVPRGTVPKEGENAPYIIPKGHYVMAAPGV	360
	*****:*****.*.: * ..: *:*****.*****	
	417FGAGRHCIG⁴⁸⁰ motif	
CBS 7966 <i>M. globosa</i>	SQVDPKIWEDASRFDPHRWLGDKAMVMNQTDDAQEDFGWGMVSTGANSPLYLFFGAGRHC	478
CBS 1878_scaffold345	TQVDPALWDDANEFPNGRWLDNSSNHLTQDTSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
CBS 7982	TQVDPALWDDANEFPNGRWLDNSSNHLTQDTSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
CBS 1878_scaffold589	TQVDPALWDDATEFNPGRWLDNSSNHLTQDMSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
CBS 4172	TQVDPALWDDATEFNPGRWLDNSSNHLTQDMSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
CBS 7110	TQVDPALWDDATEFNPGRWLDNSSNHLTQDMSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
CBS 14141	TQVDPALWDDATEFNPGRWLDNSSNHLTQDMSEQVDYGWGMVSTGGASPLYLFFGAGRHC	420
	:**** :*:..*: * ..: * ..: *:*****.*****	


Supplementary Figure 2.

Y67F mutation at nucleotide level: Strains with A to T mutation are highlighted in yellow



Supplementary Figure 3.

Validation of *PDR10* gene knockout and gene expression in *M. furfur* strains



Supplementary Table 1. MIC values for 26 *M. furfur* isolates

Strain	Source	Minimum Inhibitory Concentrations (MICs)/ µg/ml							
		AMB/(GM)	TRB/(GM)	CTZ/(GM)	MCZ/(GM)	ITZ/(GM)	FLZ/(GM)	KTZ/(GM)	VRZ/(GM)
Disease Isolates									
CBS 14141	Blood	>32	8-32 (16)	>256	>256	0.03-0.06 (0.04)	>256	0.125	4
CBS6000	Dandruff	1-4 (1.74)	8-16 (10.1)	16-128 (76.1)	256	0.06	8	1	0.125
CBS6001	Pityriasis versicolor	2-4 (2.82)	8-16 (11.3)	8-16 (12.7)	16	0.06	8	1	0.125
JLPK13	Urine	2-16 (4.42)	16->32 (26.9)	256	256	0.06	64-128 (76.1)	0.25-0.5	1-2 (1.59)
CBS5334	Infected Skin	0.25-1 (0.44)	16	16-128 (40.3)	64-256 (128)	0.03-0.06 (0.047)	4-8 (6.34)	0.25-1 (0.40)	0.125
Mal 18	Blood	1-4 (2)	4-8 (6.35)	32-64 (50.8)	64	0.03-0.06 (0.038)	4	0.25-0.5 (0.40)	0.125
Mal 24	Blood	1-4 (2)	2	32	32-64 (45.3)	0.03	4	0.25-1 (0.5)	0.06-0.125 (0.077)
Mal 25	Skin catheter insertion	1	4-16 (8)	64-256 (128)	256	0.03-0.125 (0.077)	4-8 (6.35)	0.5-1 (0.63)	0.125
Mal 26	Blood	2-16 (6.72)	8-16 (12.1)	>256	128->256	0.03-0.125 (0.078)	128	0.5-2 (1)	1-4 (1.59)
Mal 32	Skin catheter insertion	16	>32	>256	128->256	0.125	64-128 (101.6)	0.5-2 (1)	1-2 (1.59)
PM 315	Anal Swab of Neonate	1-4 (2)	8-32 (20.2)	128->256	128->256	0.06	8	0.5-2 (0.79)	0.25-0.5 (0.31)
CBS 1878	Dandruff	1-2 (1.41)	16->32 (25.4)	128-256 (203.2)	64-256 (128)	0.06	4	1-4 (2)	0.125
CBS 7019	Pityriasis Versicolor	1-4 (1.59)	8-16 (10.1)	128-256 (161.3)	256	0.03	8-16 (10.1)	0.5-1 (0.63)	0.125

GM: Geometric mean of n ≥ 3 replicates – value not indicated if all MIC values are equal across all replicates

AMB: Amphotericin B

CTZ: Clotrimazole

ITZ: Itraconazole

KTZ: Ketoconazole

TRB: Terbinafine

MCZ: Miconazole

FLZ: Fluconazole

VRZ: Voriconazole

Strain	Source	Minimum Inhibitory Concentrations (MICs)/ µg/ml							
		AMB/(GM)	TRB/(GM)	CTZ/(GM)	MCZ/(GM)	ITZ/(GM)	FLZ/(GM)	KTZ/(GM)	VRZ/(GM)
Healthy Isolates									
CBS 7982	Healthy Skin, ear	1-2 (1.23)	0.25-0.5 (0.4)	1-8 (3.17)	0.5-4 (1.59)	0.03	1	≤0.03	0.03
020#01	Healthy Skin, nose	1-4 (2.52)	1-2 (1.41)	2-4	4	0.06	4	0.06	0.125
041#01	Healthy Skin, nose	4	4	16	16	0.06	4	≤0.03	0.125
039#01	Healthy Skin, nose	1-4 (2)	2-8 (4)	8-16(10.1)	8->16	0.06	2	≤0.03	0.06
035#03	Healthy Skin, nose	2-8 (4)	2-4 (3.17)	8-16 (10.1)	8-16 (10.1)	0.06-0.25 (0.12)	2-4 (2.83)	≤0.03	0.06
CBS 9372	Back of healthy individual	1-4 (2)	4-8 (4)	64	128-256 (181.0)	0.03-0.06 (0.038)	2	0.25	0.06
CBS 9374	Chest of healthy individual	2	4-8 (5.66)	64-256 (90.5)	64-256 (128)	0.06-0.25 (0.155)	2-8 (3.17)	0.25-2 (0.63)	0.06-0.5 (0.15)
CBS 8735	Bronchial wash	16	4-16 (8)	1	1	≤0.03	2-4 (2.52)	≤0.03	0.06-0.125 (0.077)
047 SC1	Healthy Scalp isolate	4	2	0.5	2	0.125	2-4 (2.83)	≤0.03	0.125
003 SC2	Healthy Scalp isolate	4	2	16	16-64 (40.3)	0.03-0.06 (0.048)	32	≤0.03	0.5
CBS 7710	Skin of man	16	2	4	2	0.25-0.5 (0.35)	8	≤0.03	0.125-0.25(0.16)
043#01	Healthy Skin, nose	4	8-16 (11.3)	16	8-16 (11.3)	0.06	4	0.03	0.125
001#01	Healthy Skin, nose	2	16	128	64	0.125	4	0.5	0.125

GM: Geometric mean of n ≥ 3 replicates – value not indicated if all MIC values are equal across all replicates

AMB: Amphotericin B
TRB: Terbinafine

CTZ: Clotrimazole
MCZ: Miconazole

ITZ: Itraconazole
FLZ: Fluconazole

KTZ; Ketoconazole
VRZ: Voriconazole

Supplementary Table 3.

	Clotrimazole (µg/ml) MIC range¹	Mean MIC (µg/ml)
Week 0	1-4	2
Week 1	1-4	3
Week 2	2-8	5
Week 3	4-16	13.33
Week 4	4-32	17.33
Week 5	2-16	11.33
Week 6	1-4	6

Supplementary Table 6.

Primers (10 µM)	Forward (5'-3')/Reverse (5'-3')
CYP51 Y67F region	CGTGCTTTGGCAGTTGCT/AGAACTTGCTCATCAGGC
7982_F1 1.5kb forward flanking arm	GTTTTCCAGTCACGACGTTGTA AAACCGTATATCTCACACAGATCG/ CGAGGATCTGCACCGTGGA CCGTAGGTCACCGCCGAGC
7982_F2 1.5kb reverse flanking arm	CTGGGTCAGACATAGGAGAGGACG GCGGCGATTCTTTCCACCC/ CAGCTATGACATGATTACGAATTCTTAATT CAGCGAGTTGTAGAAGAACC
14141_F1	CTGCAAGGCGATTAAGTTG GGAGGCACATCTATATGGCTTTCC/ CGAGGATCTGCACCGTGGA ACCGCCGAGCCCACTA
14141_F2	CTGGGTCAGACATAGGAGAGGACG AGAAGCCTAGTGTTGTGGTCTAC /CAGCTATGACATGATTACGAATTCTTAATT GGCTGTAGTTGTGTGCCCA
ITS primer (5F4R)	TCCGTAGGTGAACCTGCGG/ TCCTCCGCTTATTGATATGC
Actin	CCCGCTGAACCCSAAGGC/ CACACCGTCACCCGAGTC
PDR10	ATGTTCTTGCGTACTACCG/ GACAGCACGAGCGACATAAA

¹ Values represent a range observed over triplicate AFST assays performed at each time point